NexLife vs Yucca Health

NexLife vs Yucca Health at every dose

A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.

What differs beyond price

Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.

Which one, for whom

If you want the lowest total cost: NexLife at about $2,580 for a first year.

If you want budget certainty: neither has an advantage — both use the same pricing model.

If you want to verify the supply chain: neither names a dispensing pharmacy in a way we could verify — ask both directly.

If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.

Switching between them

Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 2.5 mg is a month of lost progress no price difference recovers.

If you are already on one of them

Moving from Yucca Health to NexLife is worth $516 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 2.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

NexLife charges no recurring fee on top of medication. Yucca Health charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

NexLife: async, labs not required, 1:1 call included. Yucca Health: async, labs not required, none published.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

NexLife: 6 named partners. Yucca Health: named physicians.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

Which is cheaper depends on where you land

A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.

Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.

What each one is actually charging for

NexLife: $215 medication, no recurring fee. Yucca Health: $258 medication, no recurring fee.

Both use the same fee structure, so the medication figures are directly comparable — which is unusual enough in this market to be worth stating.

What committing to a term does to the answer

NexLife publishes $186 a month on its 12-month plan, saving $348 a year against monthly billing.

Yucca Health publishes $225 a month on its 6-month plan, saving $396 a year.

Prepaying converts a monthly decision into one that is effectively final, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: you would be committing against the most likely reason to stop. After a stable cycle at maintenance it is reasonable, and it can change which of these two is cheaper.

Where the money actually separates

A single annual figure hides when the gap opens. Tracked month by month through a first year you can see whether the difference is front-loaded during titration or accumulates quietly at maintenance.

Across the year the gap reaches $516, roughly 17% of the larger total and about 2.4 months of therapy at NexLife's maintenance rate. Over three years at a stable dose the same difference compounds to roughly $1,548.

Does the answer change with your dose?

NexLife is cheaper at every strength, so this comparison does not turn on where you settle. The decision moves to what else differs: disclosure, care model, commitment terms and behaviour when a shipment fails.

Commitment and what each puts at risk

NexLife publishes a prepaid rate of $186 a month on its 12-month plan. Yucca Health publishes a prepaid rate of $225 a month on its 6-month plan.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: it commits against the most likely reason to stop. After a stable cycle at maintenance it is reasonable.

Care model and what you can verify

NexLife: async, labs not required, pharmacy 6 named partners, cancellation cancel any time on monthly.

Yucca Health: async, labs not required, pharmacy named physicians, cancellation 6-month term.

Where one names a pharmacy and the other does not, that difference outranks a modest price gap. It is the only disclosure that lets you check a public register before injecting something weekly, and it costs a programme nothing to publish.

If you are already on one of them

Moving from Yucca Health to NexLife is worth $516 over a year, about 2.4 months of therapy at the cheaper rate. Set that against two real switching costs: a supply gap while an intake is reviewed, and the possibility that a new prescriber restarts titration.

Ask about dose continuation in writing before cancelling anything. A month back at 2.5 mg is a month of lost progress that no price difference recovers, and it is the most common regret reported by people who switched for a small saving.

What neither table can tell you

Shipping reliability, how fast a clinician actually replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does, and we hold no measurements of them we would defend, so they are absent rather than estimated.

The one usable proxy is what each programme publishes before it has your money. A programme that states its price at every dose, names its pharmacy and puts cancellation terms in writing has already told you something about how it behaves when there is a problem.

Running this comparison again later

Both figures carry a capture date and both will change. Programmes do not notify existing patients when a competitor drops below them, and several tracked programmes moved pricing more than once in the past year.

Re-run this at your actual maintenance dose annually, and treat any figure older than a month as needing a re-check before you act on it.

Where both of these sit in the wider market

NexLife at $2,580 and Yucca Health at $3,096 for a first year sit against a market running from $2,580 to $7,164. Both are at the cheaper end of what we track.

If neither is close to the cheapest tracked route, the useful question is not which of these two wins but why you are choosing between these two at all. The comparison matrix will show what else is available at your dose in about ten seconds.

If you are already on one of them

Moving from Yucca Health to NexLife is worth $516 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 2.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

NexLife charges no recurring fee on top of medication. Yucca Health charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

NexLife: async, labs not required, 1:1 call included. Yucca Health: async, labs not required, none published.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

NexLife: 6 named partners. Yucca Health: named physicians.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

Which is cheaper depends on where you land

A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.

Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.

What each one is actually charging for

NexLife: $215 medication, no recurring fee. Yucca Health: $258 medication, no recurring fee.

Both use the same fee structure, so the medication figures are directly comparable — which is unusual enough in this market to be worth stating.

What committing to a term does to the answer

NexLife publishes $186 a month on its 12-month plan, saving $348 a year against monthly billing.

Yucca Health publishes $225 a month on its 6-month plan, saving $396 a year.

Prepaying converts a monthly decision into one that is effectively final, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: you would be committing against the most likely reason to stop. After a stable cycle at maintenance it is reasonable, and it can change which of these two is cheaper.

The gap between NexLife and Yucca Health

NexLife costs $43 a month less than Yucca Health at a 10 mg maintenance dose — $215 against $258 — which compounds to $516 across a first year, a 17% difference.

Both dispense the same molecule. The gap is overhead, clinical wrap, pharmacy sourcing and margin, not a difference in what arrives in the vial.

Same structure, different number

Both price flat across the ladder, so the comparison stays stable wherever you settle. NexLife is cheaper at every strength, by $43 a month at maintenance.

When two programmes share a pricing structure, the remaining differences are care model, pharmacy disclosure and cancellation terms rather than arithmetic.

If you are weighing semaglutide instead

Both programmes carry compounded semaglutide as well as tirzepatide. NexLife prices semaglutide at $145 a month all-in against $215 for tirzepatide; Yucca Health prices it at $146 against $258. On semaglutide the cheaper of the two is NexLife, by $1 a month.

Note that the tirzepatide answer and the semaglutide answer are the same programme here. That simplifies the decision: one programme is cheaper on both molecules.

The semaglutide premium runs $70 a month at NexLife and $112 at Yucca Health. Tirzepatide costs more at both because the peptide is longer and harder to synthesise, not because either programme is marking it up unusually. Whether that premium is worth paying is a clinical question: SURMOUNT-5 reported greater mean weight reduction on tirzepatide over 72 weeks, while semaglutide carries the larger cardiovascular outcomes evidence base.

Pharmacy disclosure on both sides

Both programmes name the dispensing pharmacy before purchase, so both can be checked on a state board register before you commit.